Clascoterone cream (marketed as Winlevi) represents a genuine breakthrough in acne treatment—the first topical antiandrogen approved by the FDA for acne in August 2020, and the first completely new acne mechanism to reach the market in nearly 40 years. Rather than addressing bacterial overgrowth or inflammation alone, clascoterone works at the hormonal root of acne by blocking androgen receptors directly in the skin, competing with the hormone dihydrotestosterone (DHT) that drives excess sebum production and inflammatory responses in acne-prone areas.
Since its U.S. launch in November 2021, dermatologists have prescribed it to patients who don’t respond well to retinoids, antibiotics, or isotretinoin—offering an option for those whose acne is particularly hormone-sensitive but who aren’t candidates for systemic hormonal therapies. This article explores how clascoterone works, what clinical evidence shows about its effectiveness, how it compares to existing treatments, and what patients should realistically expect from this novel acne therapy.
Table of Contents
- How Does Clascoterone Target Androgens in Acne?
- Clinical Evidence—What Phase 3 Trials Showed
- Safety Profile and Systemic Effects
- How Clascoterone Compares to Existing Acne Treatments
- Realistic Expectations and Combination Therapy
- Recent Regulatory Recognition and International Adoption
- The Future of Topical Hormonal Treatments
- Conclusion
How Does Clascoterone Target Androgens in Acne?
Clascoterone operates by a mechanism fundamentally different from every other topical acne medication currently available. Instead of killing bacteria or increasing skin cell turnover, it acts as a topical androgen receptor antagonist—meaning it sits on the androgen receptors in the pilosebaceous units (the hair follicle, sebaceous gland, and surrounding tissue) and blocks DHT from binding to those same receptors. This prevents DHT from stimulating sebum overproduction and the inflammatory cascade that drives comedone formation and bacterial colonization. The drug achieves this action with minimal systemic absorption, meaning it stays localized to the skin and doesn’t interfere with hormone levels elsewhere in the body—a critical distinction from oral hormonal therapies like spironolactone or birth control pills that affect circulating androgens throughout the entire system.
The significance of this mechanism lies in its specificity. Acne hormones work by causing the oil glands to overproduce sebum and simultaneously increasing the inflammatory signaling molecules that attract immune cells. By blocking androgen receptors directly in the skin, clascoterone suppresses both effects—sebum production drops, and the inflammatory environment in the follicle becomes less hospitable to the *Cutibacterium acnes* bacteria that proliferate in oily conditions. For patients whose acne is driven primarily by hormonal sensitivity (often called hormonal acne or androgen-sensitive acne), this targeted approach can be more effective than antibiotics alone, which only address the bacterial component.
Clinical Evidence—What Phase 3 Trials Showed
Two Phase 3 randomized controlled trials enrolled 1,440 patients total and evaluated clascoterone cream versus a placebo (vehicle) cream applied twice daily for 12 weeks. The results demonstrated clear superiority: at 12 weeks, 19.9% of patients using clascoterone achieved treatment success (defined as at least a 2-grade improvement on the investigator’s static global acne assessment) compared to only 7.7% in the placebo group—a nearly threefold difference. More granular lesion counts showed reductions of 40% in total acne lesions with clascoterone versus 26% with placebo, with inflammatory lesions dropping 19.7% versus 14%, and noninflammatory lesions (blackheads and whiteheads) declining 20.8% versus 11.9%. However, it’s important to contextualize these numbers: while statistically significant, the absolute success rate of about 20% means that four out of five patients won’t achieve complete clearance at 12 weeks.
This is lower than what many patients see with isotretinoin (which clears acne in 90% of cases) or even with oral antibiotics combined with retinoids in appropriately selected patients. The advantage of clascoterone is not that it’s the strongest acne treatment available, but rather that it provides an option for patients who can’t tolerate or aren’t candidates for those alternatives. Efficacy likely improves beyond 12 weeks with continued use, and combining clascoterone with other agents (such as a retinoid or benzoyl peroxide) would be expected to yield better results, though such combination data in the pivotal trials wasn’t emphasized in regulatory submissions.
Safety Profile and Systemic Effects
One of the primary concerns with any hormonal acne treatment is whether it might cause unwanted systemic effects—hormonal changes, reproductive risks, or unexpected side effects from drugs entering the bloodstream. Clascoterone’s safety record addresses this worry directly: the drug has minimal systemic absorption due to its topical formulation, and clinical trials found no systemic antiandrogenic effects. Patients don’t experience the potential side effects associated with oral antiandrogens like spironolactone (which can cause hyperkalemia, irregular periods, or breast tenderness) or hormonal contraceptives (which carry small but real risks of blood clots and stroke).
Adverse events in the trials were predominantly mild and matched the placebo group closely. The most commonly reported issues were local skin reactions—expected with any twice-daily topical cream application—along with nonskin complaints like nasopharyngitis (a cold-like illness), headache, and oropharyngeal pain that were no more frequent than in placebo-treated patients. The drug is approved for ages 12 and older, meaning even young teens with severe hormonal acne can use it without the systemic hormonal risks that would accompany isotretinoin or oral contraceptive therapy. The main caveat is that individual skin tolerance varies; some patients experience irritation or dryness at the application site, which can usually be managed by reducing frequency to once daily or applying moisturizer beforehand.
How Clascoterone Compares to Existing Acne Treatments
Situating clascoterone within the existing acne treatment landscape reveals both its unique advantages and its realistic limitations. Benzoyl peroxide and salicylic acid are inexpensive, available over-the-counter, and work via antibacterial and exfoliating mechanisms respectively—effective for mild acne but limited against moderate-to-severe cases. Topical retinoids (tretinoin, adapalene, tazarotene) address acne by normalizing skin cell turnover and have the strongest evidence for monotherapy efficacy among topicals, but they require months to work, cause initial irritation and flaking, and are contraindicated in pregnancy. Topical antibiotics (clindamycin, erythromycin) kill bacteria but face growing resistance concerns and work best only in combination with benzoyl peroxide or retinoids. For patients with significant hormonal acne who want to avoid systemic effects, the comparison gets more interesting.
Oral spironolactone directly lowers circulating androgens and is highly effective for hormonal acne, especially in women, but requires ongoing monitoring of potassium levels and kidney function, and causes side effects in about 20% of users. Oral isotretinoin is the gold standard for severe acne—clearing it in 90% of patients—but carries teratogenic risk, requires monthly pregnancy tests and liver function monitoring, and causes chronic dry skin in nearly all users. Clascoterone, by contrast, offers a middle ground: stronger local efficacy than standard topicals but without the systemic risks of isotretinoin or spironolactone. The trade-off is that its overall efficacy is lower than these systemic therapies. For a 16-year-old with moderate hormonal acne, clascoterone might be an excellent first choice before considering oral medications. For a 25-year-old with severe nodular acne, isotretinoin would likely be more appropriate despite its stricter requirements.
Realistic Expectations and Combination Therapy
Patients starting clascoterone should understand that this is not a quick fix. The Phase 3 trials measured outcomes at 12 weeks, but individual improvement often extends beyond that timeframe—some dermatologists recommend assessing efficacy at 16 weeks of consistent twice-daily application before deciding to switch to a different approach. Additionally, clascoterone works synergistically with other acne treatments, and many dermatologists prescribe it alongside benzoyl peroxide or a retinoid to boost overall efficacy. There’s a logical rationale here: clascoterone addresses the hormonal drive to produce sebum, a retinoid normalizes skin cell turnover, and benzoyl peroxide kills bacteria—three different mechanisms working in parallel.
One important limitation to consider is that clascoterone does nothing to address bacterial resistance, which is why combination therapy remains the standard of care. A patient using clascoterone monotherapy might see some benefit, but adding benzoyl peroxide (even just 2.5% or 5% cream) would likely improve results significantly. Similarly, if a patient is also using an oral antibiotic (doxycycline, minocycline), the combination creates multiple layers of treatment that reduce the risk of antibiotic resistance. Cost is another real-world consideration: clascoterone is available only by prescription and, while many insurance plans now cover it following FDA approval and American Academy of Dermatology guideline inclusion in 2024, out-of-pocket costs can reach $100–$200 per month without insurance, making it less accessible than generic retinoids or benzoyl peroxide.
Recent Regulatory Recognition and International Adoption
The American Academy of Dermatology’s 2024 updated acne guidelines included conditional recommendations for topical clascoterone, a significant clinical endorsement that signals mainstream acceptance among dermatologists. This inclusion came several years after FDA approval, reflecting the time required for evidence to accumulate and expert consensus to form. Beyond the United States, clascoterone recently gained regulatory approval in Europe, where it’s undergoing launch and integration into treatment algorithms—a development that validates its mechanism across different regulatory frameworks and suggests durability of the clinical benefit.
The delayed international rollout (compared to the U.S.) reflects differences in regulatory timelines but doesn’t diminish the drug’s utility. For international patients, the European approval means clascoterone will become increasingly available in the coming years, offering an alternative to those currently limited to isotretinoin or oral spironolactone. In regions where isotretinoin remains difficult to access or where systemic hormonal therapies are culturally less acceptable, topical clascoterone fills an important gap.
The Future of Topical Hormonal Treatments
Clascoterone’s approval and subsequent inclusion in major dermatology guidelines suggest that topical hormonal approaches will likely expand in acne treatment. The success of a first-in-class topical antiandrogen may encourage development of other localized hormonal modulators—for instance, selective androgen receptor degraders or other agents targeting hormone sensitivity at the tissue level.
Moreover, the concept of combination topical therapy (clascoterone plus retinoid plus benzoyl peroxide in a single formulation) is likely to be explored, which could simplify regimens and improve patient adherence. Looking forward, clascoterone represents a paradigm shift in how dermatologists think about acne: moving away from the assumption that hormonal acne requires systemic intervention and toward precision topical options for hormone-sensitive skin. For patients in their teens and twenties with acne driven by androgen sensitivity, this offers a lower-risk entry point into more effective treatment before considering systemic therapies.
Conclusion
Clascoterone cream (Winlevi) is the first new acne mechanism approved in nearly 40 years and the first topical antiandrogen to reach the FDA—representing a meaningful advance for patients with hormonal or androgen-sensitive acne. Phase 3 trials show clear efficacy above placebo with a favorable safety profile, minimal systemic absorption, and no hormonal side effects, making it an attractive option for adolescents and young adults who might otherwise face systemic treatments with greater risks. Clinical outcomes (about 20% achieving full treatment success at 12 weeks) are realistic but not miraculous; combining clascoterone with benzoyl peroxide or a retinoid substantially improves results and remains the standard approach.
If you have moderate hormonal acne, are 12 or older, and haven’t responded adequately to topical retinoids or benzoyl peroxide alone, discussing clascoterone with your dermatologist is worthwhile. Check whether your insurance covers it (many now do, especially after 2024 AAD guideline inclusion), and plan for a 16-week treatment window before assessing efficacy. For severe acne, severe nodular acne, or cases refractory to topical therapy, systemic options like isotretinoin remain the standard—but for many patients with hormonal acne, clascoterone offers an effective, safer stepping stone.
